List view / Grid view
3 June 2014 | By Amgen
Amgen announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma...
3 June 2014 | By AstraZeneca
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors...
3 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced results of the pre-specified individual, as well as the exploratory combined, analyses of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)...
3 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab...
2 June 2014 | By kdm communications
Cresset is pleased to announce that the Centre for Chemical Biology and Therapeutics at The Institute for Stem Cell Biology and Regenerative Medicine (inStem), a state-of-the-art research institute in Bangalore, India...
2 June 2014 | By Roche
Roche announced the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA...
2 June 2014 | By Novartis
Novartis announced the appointment of Bruno Strigini, as President of Novartis Oncology...
2 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival...
2 June 2014 | By AstraZeneca
As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu presented data on a Phase II study conducted by the American National Cancer Institute...
2 June 2014 | By Amgen
...in patients with a rare and serious genetic disorder that causes high cholesterol.
2 June 2014 | By kdm communications
Avacta Analytical is pleased to announce its sponsorship of this year’s Protein Formulation Development and Drug Delivery Forum in Barcelona, Spain...
30 May 2014 | By Biogen Idec
Biogen Idec received a positive recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency for the marketing authorisation of PLEGRIDY...
30 May 2014 | By Biogen Idec
Biogen Idec announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis therapies are being featured during two neurology conferences...
30 May 2014 | By Pfizer
Pfizer Inc. announced that Morris J. Birnbaum, M.D., Ph.D., has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research...
30 May 2014 | By Sanofi
Sanofi and its subsidiary Genzyme announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmission of its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada...
